4D MOLECULAR THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 8Avg age 61Avg tenure 6.9y
DK
David Kirn
Chief Executive Officer
Age 64Since 2013-09-11Profile →
+12
Executives5
Board of directors8
DK
David Kirn→
Chairman
Age 64Since 2013-09-11
CT
Charles Theuer→
Director/Board Member
Age 62Since 2015-11-30
JC
Jacob Chacko→
Director/Board Member
Age 47Since 2019-02-28
SG
Susannah Gray→
Director/Board Member
Age 65Since 2020-06-30
JM
John Milligan→
Chairman
Age 65Since 2020-07-31
NM
Nancy Miller-Rich→
Director/Board Member
Age 67Since 2020-11-17
ST
Shawn Tomasello→
Director/Board Member
Age 67Since 2020-11-17
GS
Glenn Sblendorio→
Director/Board Member
Age 70Since 2026-01-04
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Janus Henderson Investors US LLC | 10.06 % | 5,257,897 |
| RA Capital Management LP | 9.66 % | 5,049,779 |
| Goldman Sachs Bank USA (New York) | 8.045 % | 4,205,438 |
| BlackRock Advisors LLC | 7.514 % | 3,927,922 |
| Novo Holdings A/S (Investment Company) | 6.984 % | 3,650,737 |
Catalog · 2026-07-09
Registry officers13
| Name | Role | Since | Shares |
|---|---|---|---|
| David Kirn | Chief Executive Officer | 2013-09-11 | - |
| David Kirn | Chairman | 2013-09-11 | - |
| John Milligan | Chairman | 2020-07-31 | - |
| Julie Clark | Chief Tech/Sci/R&D Officer | — | - |
| Noriyuki Kasahara | Chief Tech/Sci/R&D Officer | 2024-01-01 | - |
| Theresa Janke | Chief Operating Officer | 2018-03-31 | - |
| Charles Theuer | Director/Board Member | 2015-11-30 | - |
| Glenn Sblendorio | Director/Board Member | 2026-01-04 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 28.09Range 18–37Analysts 11
18Mean 28.0937
- Strong buy 2
- Buy 9
- Hold 1
Broker actions40 of 80
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | 25 | 2026-10-06 |
| B of A Securities | Maintained | Buy | 33 | 2026-09-29 |
| Cantor Fitzgerald | Upgrade | Overweight | 20 | 2026-09-14 |
| B. Riley Securities | Initiated | Buy | 37 | 2026-07-31 |
| HC Wainwright & Co. | Reiterated | Buy | 36 | 2026-07-20 |
| HC Wainwright & Co. | Reiterated | Buy | 36 | 2026-03-20 |
| RBC Capital | Maintained | Outperform | 35 | 2026-03-19 |
| Chardan Capital | Maintained | Buy | 26 | 2026-03-19 |
| Barclays | Initiated | Overweight | 33 | 2026-01-28 |
| Chardan Capital | Maintained | Buy | 26 | 2025-12-18 |
| RBC Capital | Maintained | Outperform | 32 | 2025-11-11 |
| Barclays | Maintained | Overweight | 33 | 2025-11-11 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.